CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
拓展 CAR-T 细胞疗法的作用：从 B 细胞血液系统恶性肿瘤到自身免疫性风湿病
英文原题：Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
查看英文原题
Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法是一种免疫治疗方式，通过将 CAR 与淋巴细胞（主要是 T 细胞）结合，使其重定向并特异性识别和清除目标抗原。CAR 与靶细胞表面抗原结合可引发强烈 T 细胞活化和稳健的抗肿瘤免疫应答。CAR-T 主要用于血液系统恶性肿瘤（如晚期 B 细胞癌），但近期研究也显示，这种新型免疫疗法在自身免疫性风湿病中取得了前所未有的成功。本文综述 CAR-T 在风湿病学领域的最新进展，并根据疗效和安全性数据讨论其在真实临床实践中的应用局限。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy where the lymphocytes, mostly T-cells, are redirected to specifically recognize and eliminate a target antigen by coupling them with CARs. The binding of CAR and target cell surface antigens leads to vigorous T cell activation and robust anti-tumor immune responses.
Areas of implication of CAR T-cell therapies include mainly hematological malignancies (i. e. , advanced B-cell cancers); however, recent studies have proven the unprecedented success of the new immunotherapy also in autoimmune rheumatic diseases.
We aim to review the recent advances in CAR T-cell therapies in rheumatology but also to address the limitations of their use in the real clinical practice based on the data on their efficacy and safety.
论文信息
- 作者
- Shumnalieva R、Velikova T、Monov S
- 单位
- Department of Rheumatology, Clinic of Rheumatology, Medical University-Sofia, Faculty of Medicine, Sofia, Bulgaria.
- 文献类型
- 综述
- 期刊
- International journal of rheumatic diseases2024 May
- 原文标识
- PubMed 38742463 · DOI 10.1111/1756-185X.15182